SST2 (IHC-grade), Somatostatin Receptor 2 Antibody

Figure 1. Immunohistochemical identification of Somatostatin Receptor 2 in human neuroendocrine tumor tissue. Sections were dewaxed, microwaved in citric acid, and incubated with anti-SST2 (Somatostatin Receptor 2) antibody (7TM0356N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, SST2 receptors were uniformly detected at the plasma membrane of nearly all tumor cells.

Figure 2. Immunohistochemical identification of Somatostatin Receptor 2 in human growth-hormone-producing pituitary adenoma tissue. Sections were dewaxed, microwaved in citric acid, and incubated with anti-SST2 (Somatostatin Receptor 2) antibody (7TM0356N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, SST2 receptors were uniformly detected at the plasma membrane of nearly all tumor cells.

Figure 3. Immunohistochemical identification of Somatostatin Receptor 2 in human anterior pituitary. Sections were dewaxed, microwaved in citric acid, and incubated with anti-SST2 (Somatostatin Receptor 2) antibody (7TM0356N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution.Color was developed by incubation in 3-amino-9-ethylcarbazole (AEC), and sections were counterstained with hematoxylin. Note, SST2 receptors were detected on a distinct population of cells in the anterior pituitary.

Figure 4. Immunohistochemical identification of Somatostatin Receptor 2 in human pancreatic islets. Sections were dewaxed, microwaved in citric acid, and incubated with anti-SST2 (Somatostatin Receptor 2) antibody (7TM0356N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution.Color was developed by incubation in 3-amino-9-ethylcarbazole (AEC), and sections were counterstained with hematoxylin. Note, SST2 receptors were detected at the plasma membrane of nearly all cells in human pancreatic islets.

Figure 5. Immunofluorescent identification of Somatostatin Receptor 2 in human enteric ganglia cells. Sections were dewaxed, microwaved in citric acid, and incubated with a mixtures of anti-SST2 (Somatostatin Receptor 2) antibody (7TM0356N-IC)(Red) at a dilution of 1:100 and mouse anti-SRIF antibody (Green). Note, SST2 receptors were detected at the plasma membrane of enteric ganglia cells in close proximity to SRIF-containing nerve fibers and terminals.

Figure 6. Immunocytochemical identification of Somatostatin Receptor 2 in transfected HEK293 cells. HEK293 cells stably expressing the Somatostatin Receptor 2 (SST2) were either not exposed or exposed to 1 μM SRIF (somatotropin release inhibiting factor) for 30 min and immunocytochemically stained with anti-SST2 (Somatostatin Receptor 2) antibody (7TM0356N-IC) at a dilution of 1:200. Note, SST2 receptors were confined to the plasma membrane in untreated cells (0 min). SST2 receptors were seen in perinuclear clusters of vesicles after 30 min SRIF exposure.

Figure 7. Western blot analysis of Somatostatin Receptor 2 in mouse brain in vivo. Brains from SST2-deficient mice (SST2-KO) and their wild-type littermates (SST2-WT)were dissected, homogenated and immunoblotted using anti-SST2 (Somatostatin-Receptor 2) antibody (7TM0356N-IC) at a dilution of 1:1000. Note, absence of SST2 receptors in SST-KO but not in SST2-WT mice.

Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R, Höllt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000 May;6(5):1865-74. PubMed PMID: 10815909.

Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol. 2008 Feb 20;26(6):963-70. doi: 10.1200/JCO.2007.12.7431. PubMed PMID: 18281671.

Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab. 2008 Nov;93(11):4519-24. doi: 10.1210/jc.2008-1063. Epub 2008 Aug 12. PubMed PMID: 18697876.

Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab. 2009 Feb;94(2):654-61. doi: 10.1210/jc.2008-1919. Epub 2008 Nov 11. PubMed PMID: 19001514.

Shi TJ, Xiang Q, Zhang MD, Barde S, Kai-Larsen Y, Fried K, Josephson A, Glück L, Deyev SM, Zvyagin AV, Schulz S, Hökfelt T. Somatostatin and its 2A receptor in dorsal root ganglia and dorsal horn of mouse and human: expression, trafficking and possible role in pain. Mol Pain. 2014 Feb 13;10:12. doi: 10.1186/1744-8069-10-12. PubMed PMID: 24521084; PubMed Central PMCID: PMC3943448.